Company summary
Haleon is one of the world's largest consumer-health companies, owning brands including Sensodyne, Panadol, Advil, Centrum, Voltaren and Otrivin. It focuses entirely on everyday health products sold without prescription.
← Back to the 350
HLN
Haleon
Pharmaceuticals & Biotechnology
- Index
- FTSE 100
- ISIN
- Not specified
- Book status
- 2026 edition — current
Key activities
Oral health, pain relief, vitamins and supplements, respiratory health, digestive health and therapeutic skin-health products, supported by global manufacturing, marketing and consumer-health research.
Key markets
More than 100 consumer markets worldwide, with major positions in North America, Europe and Asia and growing investment in China, India and other emerging markets.
Key drivers
Brand growth, pricing and volume, premium innovation, oral-health penetration, emerging-market expansion, cost savings, debt reduction and continued shareholder returns through dividends and buybacks.
Key risks
Consumer spending weakness, retailer pressure, product recalls, regulatory changes, currency movements, raw-material inflation, litigation and failure to deliver planned cost savings or innovation.
Recent Developments
30 July 2026: first-half revenue was £5.60bn and adjusted operating profit £1.36bn, while free cash flow reached £769m. Haleon raised the interim dividend to 2.4p and continued its £500m buyback while investing in new manufacturing capacity in China and India.
Dividend notes
Pays interim and final dividends. The 2025 final dividend of 4.9p went ex-dividend on 9 April 2026 and was paid on 14 May. The 2026 interim dividend is 2.4p, a 9% increase; investors should check Haleon's timetable for its payment and ex-dividend dates.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.